Aptose Biosciences Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Note 12 - Share Capital (Details Textual)

Note 12 - Share Capital (Details Textual) - USD ($)									5 Months Ended	11 Months Ended	12 Months Ended		18 Months Ended
Note 12 - Share Capital (Details Textual) - USD ($)	Feb. 26, 2025	Feb. 07, 2025	Nov. 25, 2024	Sep. 11, 2024	Jun. 03, 2024	Jan. 30, 2024	Sep. 06, 2023	May 25, 2023	May 30, 2024	Apr. 30, 2024	Dec. 31, 2024	Dec. 31, 2023	May 30, 2024	Mar. 14, 2025	Sep. 30, 2024	Sep. 05, 2024	Jun. 18, 2024	Apr. 01, 2024	Feb. 29, 2024	Aug. 10, 2023	Dec. 31, 2022	Dec. 09, 2022	Nov. 04, 2021
Nasdaq Listing Rule, minimum requirement for stockholders' equity											$ 2,500,000
Negative shareholder's equity											$ (4,543,000)	$ (2,901,000)									$ 37,741,000
Common Stock, Shares Outstanding											2,006,028	264,745
Common Shares [Member]
Negative shareholder's equity											$ 457,404,000	$ 444,806,000									$ 437,520,000
Subsequent Event [Member]
Reverse stock split	1-for-30 reverse stock split
Nasdaq Listing Rule, minimum requirement for stockholders' equity														$ 2,500,000
Hanmi Pharmaceuticals Co Ltd [Member]
Warrants to purchase common shares, number of warrants											77,972
Shares Issued, Price Per Share (in dollars per share)											$ 51.3
Proceeds from Issuance of Common Stock							$ 3,000,000
Number of common shares held											99,647												7,190
Change in fair value of warrants																	$ 700,000
Common Stock, Shares Outstanding											99,647	29,471
Hanmi Pharmaceuticals Co Ltd [Member] \| Common Shares [Member]
Number of shares sold							22,281
Maximum [Member] \| Subsequent Event [Member]
Stock Issuance Program, Authorized Amount		$ 25,000,000
Maximum [Member] \| Hanmi Pharmaceuticals Co Ltd [Member]
Investment for ownership interest																				$ 7,000,000
Percentage of investment																				19.99%
Minimum [Member] \| Hanmi Pharmaceuticals Co Ltd [Member]
Percentage of common shares outstanding.																			19.99%
Private placement issuance percentage																			20.00%
Commitment Shares [Member] \| Keystone [Member]
Common shares issued											$ 23,000
Commitment Shares [Member] \| Subsequent Event [Member]
Stock issuance program authorized shares		8,020
2023 Committed Equity Facility [Member]
Stock issuance program authorized shares								838
Stock Issuance Program, Authorized Amount								$ 25,000,000
Percentage of common shares outstanding.								19.99%
Common shares issued (in shares)												24,016
Shares Issued, Price Per Share (in dollars per share)												$ 87.3
Proceeds from Issuance of Common Stock												$ 2,100,000
2023 Committed Equity Facility [Member] \| Keystone [Member]
Financing costs including underwriting costs, professional fees and recognition of deferred financing costs										$ 168,000	$ 82,000
Percentage of common shares outstanding.																		19.99%
Common shares issued (in shares)										41,019	17,003
Shares Issued, Price Per Share (in dollars per share)										$ 68.1	$ 40.8
Proceeds from Issuance of Common Stock										$ 2,800,000	$ 694,000
2023 Committed Equity Facility [Member] \| Commitment Shares [Member]
Common shares issued (in shares)												483
2023 Committed Equity Facility [Member] \| Commitment Shares [Member] \| Keystone [Member]
Common shares issued (in shares)										838	329
2023 Committed Equity Facility [Member] \| Initial Commitment Shares [Member]
Common shares issued (in shares)								251
Stock Issuance, Percent of Cash Commission to Broker								30.00%
2023 Committed Equity Facility [Member] \| First Back-End Commitment Shares [Member]
Common shares issued (in shares)								251
Stock Issuance, Percent of Cash Commission to Broker								30.00%
November 2024 Public Offering [Member]
Warrants to purchase common shares, exchange price			$ 6
Warrants, Remaining contractual life			5 years
Transaction cost including placement agent fees and professional fees			$ 1,100,000
Placement agent fees			600,000
Professional fees			$ 500,000
Number of shares sold			1,333,333
Sale of stock price per share			$ 6
Proceeds from Issuance of Common Stock, Gross			$ 8,000,000
November 2024 Public Offering [Member] \| Alliance Global Partners [Member]
Warrants to purchase common shares, exchange price			$ 8.25
Warrants, Remaining contractual life			5 years
Warrants issued			53,333
November 2024 Public Offering [Member] \| Maximum [Member]
Warrants to purchase common shares, number of warrants			666,599
Private Placement [Member]
Proceeds from Issuance of Common Stock, Gross						$ 4,000,000
Private Placement [Member] \| Series A Warrants [Member]
Warrants to purchase common shares, exchange price					$ 34.5
Warrants, Remaining contractual life					5 years
Private Placement [Member] \| Series B Warrants [Member]
Warrants to purchase common shares, exchange price					$ 34.5
Warrants, maturity date					Mar. 05, 2026
Private Placement [Member] \| Hanmi Pharmaceuticals Co Ltd [Member]
Warrants to purchase common shares, exchange price						$ 51.3
Warrants, maturity date						Jan. 31, 2029
Common shares issued (in shares)						70,175
Shares Issued, Price Per Share (in dollars per share)						$ 57
Cash transaction costs						$ 300,000
Private Placement [Member] \| Hanmi Pharmaceuticals Co Ltd [Member] \| Common Shares [Member]
Warrants to purchase common shares, number of warrants						77,972					77,972	0
Private Placement [Member] \| Maximum [Member] \| Series A Warrants [Member]
Warrants to purchase common shares, number of warrants					128,500
Private Placement [Member] \| Maximum [Member] \| Series B Warrants [Member]
Warrants to purchase common shares, number of warrants					128,500
Registered Direct Offering [Member]
Number of shares sold					60,000
Shares Issued, Price Per Share (in dollars per share)															$ 34.5
Proceeds from Issuance of Common Stock, Gross					$ 4,400,000
Cash transaction costs					$ 400,000
Registered Direct Offering [Member] \| H.C. Wainwright [Member]
Warrants to purchase common shares, exchange price					$ 43.13
Warrants, maturity date					Jun. 03, 2029
Warrants issued					6,423
Registered Direct Offering [Member] \| Pre Funded Warrants [Member]
Warrants to purchase common shares, exchange price					$ 0.03
Warrants, maturity date					Jun. 25, 2029
Warrants issued					68,500
September 2024 Common Share Issuance [Member]
Warrants to purchase common shares, exchange price				$ 0.03
Percentage of shares outstanding																20.00%
Pre-Funded warrants exercised				68,500
Cash proceeds				$ 2,000
Common shares issued (in shares)				6,850
Public Offering [Member]
Warrants to purchase common shares, exchange price						$ 51.3
Warrants, maturity date						Jan. 30, 2029
Common shares issued (in shares)						188,304
Proceeds from Issuance of Common Stock, Gross						$ 9,700,000
Cash transaction costs						$ 1,600,000
Public Offering [Member] \| Newbridge Warrants [Member]
Warrants to purchase common shares, exchange price						$ 64.13
Public Offering [Member] \| Common Shares [Member]
Warrants to purchase common shares, number of warrants						188,174
Public Offering [Member] \| Common Shares [Member] \| Newbridge Warrants [Member]
Warrants to purchase common shares, number of warrants						18,084
Public Offering [Member] \| Hanmi Pharmaceuticals Co Ltd [Member]
Premium share price (as a percent)						11.00%
Over-Allotment Option [Member]
Shares Issued, Price Per Share (in dollars per share)						$ 51.3
Common shares issued upon exercise of stock options						$ 24,561
The 2022 ATM Offering [Member]
Stock Issuance Program, Authorized Amount																						$ 50,000,000
Common shares issued (in shares)									2,717
Common shares issued											$ (21,000)	$ 1,809,000
Shares Issued, Price Per Share (in dollars per share)									$ 36.6				$ 36.6
Proceeds from Issuance of Common Stock, Gross									$ 100,000				$ 2,000,000
Proceeds from Issuance of Common Stock									$ 121,000		$ (21,000)	$ 1,809,000	$ 2,000,000
Stock Issuance, Percent of Cash Commission to Broker											3.00%
The 2022 ATM Offering [Member] \| Common Shares [Member]
Common shares issued (in shares)											2,717	11,198
Common shares issued											$ (21,000)	$ 1,809,000